Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (91-100 of 265) with videos related to

Pageof 27
Sort By:
Plos One|July 21, 2012
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trialShernan G Holtan, Preston D Steen, Nathan R Foster, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Future Oncology (London, England)|April 13, 2025
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, <i>ESR1</i>-mutated, metastatic breast cancerMatthew P Goetz, Seth A Wander, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|October 2, 2019
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissuesJohn R Hawse, Jodi M Carter, Kirsten G M Aspros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Coprescription of tamoxifen and medications that inhibit CYP2D6Kostandinos Sideras, James N Ingle, Matthew M Ames, et al.
Mayo Clinic Proceedings|September 7, 2007
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerationsSandhya Pruthi, Judy C Boughey, Kathleen R Brandt, et al.
Molecular Endocrinology (Baltimore, Md.)|February 12, 2016
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator RegulationMing-Fen Ho, Tim Bongartz, Mohan Liu, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
BMC Bioinformatics|July 19, 2018
HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing dataSaurabh Baheti, Xiaojia Tang, Daniel R O'Brien, et al.
Pageof 27

Showing results (91-100 of 265) with videos related to

Sort By:
Pageof 27
Plos One|July 21, 2012
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trialShernan G Holtan, Preston D Steen, Nathan R Foster, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 25, 2025
Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social supportRyan Brown, Katie E Smith, Mohamed M Shanshal, et al.
Future Oncology (London, England)|April 13, 2025
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, <i>ESR1</i>-mutated, metastatic breast cancerMatthew P Goetz, Seth A Wander, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|October 2, 2019
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissuesJohn R Hawse, Jodi M Carter, Kirsten G M Aspros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Coprescription of tamoxifen and medications that inhibit CYP2D6Kostandinos Sideras, James N Ingle, Matthew M Ames, et al.
Mayo Clinic Proceedings|September 7, 2007
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerationsSandhya Pruthi, Judy C Boughey, Kathleen R Brandt, et al.
Molecular Endocrinology (Baltimore, Md.)|February 12, 2016
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator RegulationMing-Fen Ho, Tim Bongartz, Mohan Liu, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2014
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesJoel M Reid, Matthew P Goetz, Sarah A Buhrow, et al.
BMC Bioinformatics|July 19, 2018
HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing dataSaurabh Baheti, Xiaojia Tang, Daniel R O'Brien, et al.
Pageof 27